Merck & Co. Signs an Exclusive Worldwide License Agreement with Taiho and Astex to Develop Targeted Therapies

 Merck & Co. Signs an Exclusive Worldwide License Agreement with Taiho and Astex to Develop Targeted Therapies

Merck’s Pifeltro (doravirine) Receives FDA Approval for Patients with HIV-1 in Appropriate Patients

Shots:

  • Taiho and Astex to receive $50M up front, up to $2.5B milestones based on preclinical, clinical, regulatory and sales plus royalties on sales. Merck (MSD outside the United States and Canada) to get exclusive worldwide rights to commercialize Taiho and Astex’s therapies and will also fund the R&D activities
  • Additionally, the companies will combine their respective preclinical candidate plus the data with knowledge and expertise from their respective research programs. Taiho to get co-commercialization rights in Japan with an option to promote in certain areas of South East Asia
  • The companies are focused on the development of multiple targeted therapies including KRAS oncogene, further accelerating the global R&D of therapies which are targeted to treat cancer

Click here to read full press release/ article | Ref: GlobeNewswire | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post